Fig. 3

Serum Tchol level combined with other biomarkers to form a composite score. A-C In recurrence-free survival as the outcome, the proportion of the serum Tchol level combined with serum LDH (A), NSE (B) and MYCN status (C) in the composite score. Red twill and white without twill represent the proportion of relapsed and non-relapsed patients in the total population, respectively. D-F In overall survival as the outcome, the proportion of the serum Tchol level combined with serum LDH (D), NSE (E) and MYCN status (F) in the composite score. Blue twill and white without twill represent the proportion of surviving and died patients in the total population, respectively. G Comparison of recurrence-free survival by serum LDH and Tchol levels in the composite score. H & I Comparison of overall survival by serum Tchol level combined with the serum LDH level (H) and MYCN status (I) in the composite score. The number of patients with recurrence-free survival or overall survival was regrouped based on a composite score of good (both biomarkers within the normal range), poor (neither biomarker within the normal range), and intermediate (only one biomarker within the normal range). The data was analyzed by Kaplan–Meier method. The curves were compared by Log-rank test